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Edited by Veli-Pekka LehtoAbstract There is accumulating evidence that the estrogen
receptor (ER) can transduce speciﬁc signals at the plasma
membrane. We tried to clarify the biological function of ER as a
signaling molecule by identifying proteins that interact with the
membrane-localized ER. The activation function 1 and 2 (AF-1
and AF-2) domains of ERa with or without the membrane-
targeting sequence were stably expressed in the breast cancer cell
line, MCF-7. The level of tyrosine phosphorylation of AF-2 was
signiﬁcantly elevated by the membrane localization. By mass-
spectrometry analysis, a- and b-tubulins and heat shock protein
70 were identiﬁed as the AF-1-associated proteins. Of these,
tubulins are associated only with membrane-targeted AF-1.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Estrogen plays an important role not only in physiological
processes such as the development of the female organs, re-
production, bone metabolism, and vascular dilatation, but also
in pathological processes such as the development of breast
cancer. Human estrogen receptor a (ERa) is a member of the
nuclear receptor superfamily and functions as a ligand-de-
pendent transcription factor [1,2]. A typical nuclear receptor
contains a variable N-terminal region called activation func-
tion 1 (AF-1), a conserved DNA binding domain (DBD), a
hinge region, and a C-terminal ligand binding domain called
activation function 2 (AF-2). Both the AF-1 and AF-2 do-
mains of ERa are shown to have a transcriptional activation
function [3], and interact with transcriptional mediators and* Corresponding author. Fax: +81-3-3542-8170.
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in the nucleus in the absence of estrogen, and more than 95% is
shown to localize in the nucleus upon estrogen stimulation
[11]. Thus, it has been believed that the action of estrogen is
mediated by nuclear-localizing ER through the regulation of
target gene transcription.
However, there are accumulating evidences that the ER can
transduce speciﬁc signals through association with other mol-
ecules outside the nucleus. In vascular endothelial cells, es-
trogen rapidly induces nitric oxide production by activating
the PI3-kinase-Akt pathway [12]. In this process, ERa is shown
to interact with the p85 subunit of PI3-kinase in a ligand-de-
pendent manner [13]. In osteoblasts, ERa is shown to mediate
the anti-apoptotic eﬀect by activating the Src/Shc/Erk (extra-
cellular signal-related kinase) pathway, and only the AF-2
domain expressed in the cytoplasm is necessary for this func-
tion [14]. These phenomena, called non-genomic actions, are
not explained by the classical genomic action of ERa because
of their rapid time course and the localization of interacting
molecules, and are recognized as novel functions of the ER.
Independent laboratories have reported the non-genomic
action of ERa in the breast cancer-derived cell line, MCF-7
[15,16]. They all observed that estrogen rapidly induces the
phosphorylation of Erk, although diﬀerent modes of action of
ERa are proposed. Migliaccio et al. [15] showed that the as-
sociation of ERa with non-receptor tyrosine kinase c-Src is the
upstream event of ERa activation and the association of two
molecules is dependent on the phosphorylation of Tyr 527 in
the AF-2 domain of ERa. On the other hand, Song et al.
demonstrated the direct association of ERa and adaptor pro-
tein Shc. This association was shown to use the AF-1 domain
of ERa and does not require the phosphorylation of Tyr 527
[16]. It seems that the paucity of endogenous ERa at the
plasma membrane makes it diﬃcult to analyze the role of ERa
at the membrane. In this study, we tried to clarify the com-
ponents of the signaling complex in MCF-7 cells by the tar-
geted expression of the ERa domain fragments at the plasma
membrane.2. Materials and methods
2.1. Plasmids
A FLAG epitope-tagged ERa AF-1 domain construct was generated
by amplifying the coding sequence of human ERa by PCR using
primers 50-CGTACCTCGAGATGACCATGACCCCTCCACAC-30blished by Elsevier B.V. All rights reserved.
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TGGCAGATTCCATAGCC- 30. This resulted in a fragment with an
XhoI site (underlined), a sequence that encodes the FLAG epitope
(DYKDDDDK), followed by a termination codon and a BamHI site
(underlined). This fragment was then digested with XhoI and BamHI
sequentially, and ligated into mammalian expression vector
pcDNA3.1())/Myc-His B (Invitrogen).
A membrane-targeted AF-1 domain construct was generated by
PCR-based site-directed mutagenesis using the AF-1 construct as a
template and primers 50-GGTAGCAACAAGAGCAAGCCCAAG-
GATGCCAGCCAGCGGACCATGACCCTCCACACC- 30 and 50-
CATCTCGAGTCTAGAGGGC. The PCR product was then digested
by DpnI that degrades only methylated template plasmids. As a result,
the N-terminal sequence of Src kinase (MGSNKSKPKDASQ encoded
by underlined 39 bp) was inserted between the XhoI site and the N-
terminal of AF-1.
A FLAG epitope-tagged ERa AF-2 domain construct was generated
using the same procedure as that of the AF-1 construct by using
primers 50-CGTACCTCGAGGCCACCATGGGCAAGAAGAACA-
GCCTGGCCTT-30 and 50-CGGGATCCTATTTGTCATCGTCGT-
CCTTGTAGTCGACTGTGGCAGGGA-30 (XhoI site and BamHI
site are underlined). A membrane-targeted AF-2 construct was also
generated by PCR-based site-directed mutagenesis using the AF-2
construct as a template and primers 50-GGTAGCAACAA-
GAGCAAGCCCAAGGATGCCAGCCAGCGGAAGAAGAACA-
GCCTGGCCTT- 30 and 50-CATGGTGGCCTCGAGTCTAG-30.
2.2. Cell culture and transfection
MCF-7 cells were maintained in Dulbecco’s Modiﬁed Eagle’s me-
dium (DMEM) with 10% FBS at 37 C with 5% CO2. When estrogen
stimulation was necessary, MCF-7 cells were cultured in phenol red
free DMEM with 5% Charcoal/Dextran Treated FBS (HyClone) for
two days. Transfection was performed using FuGENE 6 (Roche) ac-
cording to the manufacturer’s instructions. Clones were selected using
geneticin (Sigma) at a concentration of 800 lg/ml.
2.3. Antibodies and reagents
Anti-FLAG M2 monoclonal antibody and anti-a-tubulin antibody
(B-5-1-2) were purchased from Sigma. Anti-b-tubulin monoclonal
antibody (D-10) was from Santa Cruz. Anti-Hsp70 monoclonal anti-
body was purchased from Stressgen. Anti-phosphotyrosine antibody
4G10 was purchased from Upstate Biotechnology. Anti-ERa antibody
(H-184) was purchased from Santa Cruz. FITC-conjugated anti-mouse
antibody was from Santa Cruz. Alexa Fluor 488 goat anti-mouse IgG
and Alexa Fluor 594 goat anti-rabbit IgG were purchased from Mo-
lecular Probe. HRP-conjugated anti-mouse antibody was purchased
from Amersham Pharmacia. Protein-G Sepharose was purchased from
Amersham Pharmacia, b-estradiol was purchased from Sigma. No-
codazole was from Sigma.
2.4. Immunocytochemistry
Cells were grown on microscope slides in 24-well plates, washed
three times with PBS, ﬁxed with 4% paraformaldehyde/0.1 M phos-
phate buﬀer for 4 min at room temperature, washed once with PBS,
and permeabilized with 0.2% Triton X-100 in PBS. After another
washing with PBS and blocking with 2% (bovine serum albumin,
BSA)/TBST (100 mM Tris–HCl, pH 8.0, 150 mM NaCl, and 0.05%
Tween 20) for 30 min, the cells were incubated with appropriate ﬁrst
antibodies in 2% BSA/TBST for 1 h at room temperature. The cells
were washed three times with PBS and incubated with FITC-conju-
gated anti-mouse antibody (1:40) in 2% BSA/TBST. After the cells
were washed three times with PBS, microscope slides were mounted in
1.25% DABCO and 50% PBS and 50% glycerol and visualized using a
Radiance 2100 confocal microscope (Bio-Rad). In Fig. 4B, 3% BSA,
5% goat serum in TBS were used instead of 2% BSA in TBST. Alexa
Fluor 488 goat anti-mouse IgG (l:2000) and Alexa Fluor 594 goat anti-
rabbit IgG (1:2000) in 3% BSA and 5% goat serum/TBS were used as
the secondary antibodies in Fig. 4B.
2.5. Immunoprecipitation and immunoblotting
Cells were lysed in 1% Triton X-100 buﬀer (50 mMHEPES, 150 mM
NaCl, 10% glycerol, 1% Triton X-100, 1.5 mM MgCl2, and 1 mM
EGTA, 100 mM NaF, 1 mM Na3VO4, 10 lg/ml aprotinin, 10 lg/ml
leupeptin, 1 mM phenylmethylsulfonyl ﬂuoride), and the protein
concentration was measured using BCA Protein Assay (Pierce).For immunoprecipitation with anti-FLAG M2 antibody, cell lysate
(2 mg/ml) was mixed with anti-FLAG aﬃnity gel (Sigma) and rotated
for 2–12 h at 4 C. After the aﬃnity gel was washed four times with 1%
Triton X-100 buﬀer, FLAG-tagged proteins were eluted with 0.3 M
glycin HCl at pH 3.5. The elutant was removed, neutralized with 2 M
Tris–HC1 (pH 8.8), and then boiled in the sample buﬀer (0.1 M Tris–
HCl, pH 6.8, 2% SDS, 0.1 M dithiothreitol, 10% glycerol, and 0.01%
bromophenol blue) for 5 min and analyzed by SDS–PAGE. The gels
were transferred onto a polyvinylidene diﬂuoride membrane (Milli-
pore) and probed by immunoblotting. Immnunoreactive proteins were
visualized with a chemiluminescence reagent (Western Lighting, Perkin
Elmer).
2.6. Silver staining and LC/MS/MS analysis
The SDS–PAGE gels were silver stained according to a method used
previously [17].
For liquid chromatography tandem mass spectrometry (LC/MS/MS)
analysis, 12 ml of cell lysate containing 36 mg of total protein was
mixed with 200 ll of anti-FLAG aﬃnity gel and rotated for 8 h at 4 C.
The aﬃnity gel was loaded onto a chromatography column (Bio-Rad),
washed with 4 ml of 1% Triton X-100 buﬀer, and then eluted with 0.1
M glycin HCl at pH 3.5. The elutant was separated into several frac-
tions in chronological order and then neutralized with 2 M Tris–HCl
(pH 8.8). Aliquots of these fractions were subjected to SDS–PAGE
analysis, stained with SYPRO Ruby protein gel stain (Bio-Rad), and
fractions with a high concentration of FLAG-tagged protein were
selected for further analysis. The selected fractions were dialyzed using
EasySep (TOMY) in diluted (10%) PBS and then semi-lyophilized
using a SpeedVac concentrator. The concentrated samples were sub-
jected to SDS–PAGE analysis and the gel was stained with CBB (Bio-
Rad). The bands to be analyzed were dissected, digested in gel with
trypsin, and subjected to LC/MS/MS analysis.3. Results
3.1. Establishment of cell lines stably expressing a series of
domain fragments of ERa in MCF-7
To analyze molecules associated with ERa at the plasma
membrane, a series of domain constructs were generated and
named as shown in Fig. 1A. The FLAG epitope was attached
to the C-terminus of the separated AF-1 domain and the AF-2
domain of ERa. They were named AF1 and AF2, respectively.
To generate membrane-targeted constructs, the membrane-
localizing sequence of c-Src kinase was added to the N-ter-
minus of AF1 and AF2. Src kinase is a non-receptor tyrosine
kinase localizing at the plasma membrane with its myristoy-
lated N-terminal sequence. The membrane-targeted ERa do-
main constructs were named mAF1 and mAF2, respectively.
ERa has a DBD and a hinge region between the AF-1 and AF-
2 domains. Nuclear localizing signals are shown to reside in the
DBD and hinge region [11]; therefore, these regions were ex-
cluded from our domain constructs to ensure cytoplasmic
localization.
Stable transfectants that express each domain of ERa were
then established using the breast cancer cell line, MCF-7. The
expression and localization of the domain fragments were
conﬁrmed by the anti-FLAG staining of cells. It was observed
that AF1 and AF2 localized diﬀusely in the cytoplasm
(Fig. 1B: b and d), whereas mAF1 and mAF2 localized at the
periphery of the cells (Fig. 1B: c and e), showing the obvious
eﬀect of the membrane-targeting sequence.
3.2. Tyrosine phosphorylation of the AF-2 domain at the plasma
membrane
We next investigated the relationship between the tyrosine
phosphorylation of the AF-2 domain and membrane locali-
Fig. 2. Tyrosine phosphorylation of AF-2 domain at the plasma
membrane. (A) Cell lysates of AF2 and mAF2 were immunoprecipi-
tated with anti-FLAG antibody. Cells transfected with an empty
vector (VEC) were used as a negative control. Each immunoprecipitate
was subjected to immunoblotting analysis with anti-phosphotyrosine
antibody 4G10 and anti-FLAG antibody. (B) Two independent clones
of mAF2 (clones #2 and #5) were treated with either EGF (100 ng/ml)
or distilled water for 5 min. mAF2 fragments were immunoprecipitated
with anti-FLAG antibody and immunoblotted for 4G10 and anti-
FLAG antibody. Whole cell lysates (WCLs) were immunoblotted with
anti-phosphorylated p44/42 MAPK antibody and anti-p44/42 MAPK
antibody.
Fig. 1. Establishment of cell lines stably expressing a series of domain
fragments of Era in MCF-7. (A) Schematic representation of wild-type
full-length ERa (wt), FLAG epitope-tagged AF-1 domain constructs
with and without the membrane-targeting sequence (mem), and FLAG
epitope-tagged AF-2 domain constructs with or without the mem-
brane-targeting sequence. (B) Stable transfectants were immunostained
with anti-FLAG antibody. (a) Empty vector; (b) AF1; (c) mAF1; (d)
AF2; (e) mAF2. Cells were visualized with a confocal microscope at a
magniﬁcation of 600.
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tyrosine phosphorylation of the mAF2 domain fragment was
observed using phosphotyrosine speciﬁc antibody; however,
almost no phosphorylation was detected in AF2 (Fig. 2A).
This indicates that the AF-2 domain is phosphorylated ex-
clusively at the plasma membrane.
To further characterize the tyrosine phosphorylation of the
AF-2 domain, two independent clones of mAF2 cells were
stimulated by EGF. In breast cancer cells, several tyrosine
kinases, such as src family kinases [18,19] and Her-2 [20], have
been reported to be transactivated upon EGF stimulation.
However, no remarkable diﬀerence in the level of phosphory-
lation of mAF2 was observed upon EGF stimulation (Fig. 2B),
suggesting that ERa is not the substrate of tyrosine kinases
that is activated by EGF stimulation.
3.3. Screening of the membrane-speciﬁc binding partners of the
AF-1 and AF-2 domains
In order to identify the interacting molecules with each do-
main of ERa, the lysates of the stable transfectants were pu-
riﬁed with the anti-FLAG immunoaﬃnity column and
analyzed by subsequent silver staining. Several candidates for
mAF1-associated proteins were visualized by these procedures
(Fig. 3). The bands around 200 kDa (arrowhead a), 50 kDa
(arrowhead c) and 40 kDa (arrowhead d) were speciﬁcally seen
in cells expressing mAF1, while the band around 70 kDa (ar-
rowhead b) was observed in both cells expressing AF1 and
cells expressing mAF1. None of these bands was co-puriﬁed
with mAF2. These four bands were visible in the CBB gel stain
from large-scale sample preparation. Two of these were suc-
cessfully identiﬁed by LC/MS/MS analysis. The 50-kDa bandthat was speciﬁc to membrane-targeted AF1 was identiﬁed as
b-tubulin (arrowhead c in Fig. 3). The 70-kDa band which was
seen in both AF1 and mAF1 but not in mAF2 was identiﬁed as
heat shock protein 70 (Hsp70) (arrowhead b in Fig. 3). Pro-
teins speciﬁcally bound to mAF2 were not detected by this
protocol (Fig. 3), although larger-scale puriﬁcation was further
attempted.
The association of mAF1 with b-tubulin was conﬁrmed by
immunoprecipitation followed by detection with b-tubulin
antibody (Fig. 4A). This association was not detected in cells
expressing AF1, indicating that this association is localized
only at the plasma membrane. The absence of association
between mAF2 and b-tubulin suggests that the association
with b-tubulin was AF-1 domain-dependent and the mem-
brane-targeting sequence did not serve as binding site for b-
tubulin. A similar manner of association between mAF1 and
a-tubulin was also detected (Fig. 4A), which is supported by
the fact that b-tubulin forms heterodimers with a-tubulin.
To investigate physiological cooperation of tubulin and full-
length endogenous ERa, immunocytostaining of MCF-7 cells
was performed (Fig. 4B). Estrogen-dependent translocation of
ERa to the plasma membrane was observed in 15 min on es-
trogen stimulation (Fig. 4B: h and k). At the same time, re-
distribution of a-tubulin was also observed at the plasma
membrane (Fig. 4B: g and j). These two molecules showed co-
localization in the superimposed image (Fig. 4B: i and l), which
indicates possible association of these molecules in intact
Fig. 3. Associated molecules to each domain fragment of ERa detected
by silver staining. Each FLAG epitope-tagged domain fragment was
immunoprecipitated by anti-FLAG antibody. One AF1 clone, two
independent mAF1 clones (clones #5 and #8), and one mAF2 clone
were analyzed. Immunoprecipitates were subjected to SDS–PAGE,
and the gel was silver-stained. The two bands indicated by the ar-
rowheads are Hsp70 and b-tubulin, which were identiﬁed later by LC/
MS/MS analysis.
Fig. 4. Association of tubulins and Hsp70 with the AF-1 domain of
ERa. (A) Cell lysates were immunoprecipitated and immunoblotted
with anti-FLAG antibody, or anti-a- or b-tubulin antibodies as indi-
cated. One AF1 clone, two independent mAF1 clones (clones #2 and
#8), and one mAF2 clone were analyzed. (B) MCF-7 cells were treated
with estrogen (10 nM) or ethanol (same concentration used in dilution
of estrogen) for 15 min, then they were immunostained with anti-a-
tubulin antibody (a, d, g, and j: green), and anti-ERa antibody (b, e, h,
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treated only by ethanol (Fig. 4B: d–f).
To further characterize the association of mAF1 and tubu-
lins, cells expressing AF1 or mAF1 were treated with noco-
dazole, an inhibitor of tubulin polymerization. As a result,
nocodazole treatment signiﬁcantly blocked the association of
mAF1 and a-tubulin (Fig. 4C). This indicates that mAF1 has
higher aﬃnity with polymerized microtubule ﬁlaments than
with the depolymerized heterodimeric tubulin subunit.
Hsp70 was immunoprecipitated with both the AF1 and
mAF1 domain fragments, but not with mAF2 (Fig. 4D). This
suggests that the AF-1 domain is associated with Hsp70 out-
side the nucleus, but this association is not a membrane-spe-
ciﬁc event, in contrast with the case of tubulin.
and k: red). Cells were visualized with a confocal microscope at a
magniﬁcation of 600. Superimposed confocal images (c, f, i, and l:
merge) are also shown. Images without ﬁrst antibodies (a–c) are shown
as negative controls. Membranous area of estrogen stimulated MCF-7
cells was shown in magniﬁed views (j–l: enlarged). (C) One AF1 clone
and two independent mAF1 clones (clones #2 and #5) were treated
with Nocodazole (33-lmol solution in DMSO) or DMSO (negative
control) for 1 h. Cell lysates were immunoprecipitated and immu-
noblotted as indicated. (D) Cell lysates were immunoprecipitated and
immunoblotted with anti-FLAG or anti-Hsp70 antibodies as indi-
cated. One AF1 clone, two independent mAF1 clones (clones #2 and
#8), and one mAF2 clone were analyzed.4. Discussion
This study identiﬁes polymerized tubulins as speciﬁc binding
partners of the AF-1 domain of ERa at the plasma membrane
using a breast cancer cell line, MCF-7. Hsp70 was also found
to associate with the AF-1 domain although this association is
not restricted at the plasma membrane. It was demonstrated
that tyrosine phosphorylation of the AF-2 domain occurred
within the plasma membrane, while the membrane-localized
AF-2 domain failed to characterize any signiﬁcant binding
partners.
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that a subpopulation of ERa is associated with the plasma
membrane and is responsible for the rapid eﬀects of estrogen
[15,16]. However, it appears that the subpopulation of mem-
brane-associated ERa is considerably small, while the majority
of ERa translocates into the nucleus upon estrogen stimula-
tion. Therefore, we targeted the AF-1 and AF-2 domains of
ERa to the plasma membrane to overcome the small amount
of endogenous receptors at the plasma membrane.
The association of the AF-1 domain with polymerized
tubulins or microtubules was speciﬁcally detected with the
membrane-localized type of AF1, despite the wide distribu-
tion of microtubules throughout the cytoplasm. This result
led us to conjecture that the association of ERa and micro-
tubules is mediated by other molecules that reside at the
membrane. Some signaling molecules are reported to associ-
ate with microtubules at the plasma membrane. p190Rho-
GEF (guanine nucleotide exchange factor) has a PH
(pleckstrin homology) domain and localizes at the plasma
membrane. This RhoA-activating molecule, which aﬀects
transcription and actin reorganization, has also been shown
to interact directly with microtubules [21]. A small GTPase
K-Ras, which can transduce signals to Erk, is another mole-
cule shown to associate with microtubules at the plasma
membrane [22]. It is possible that ERa forms a complex with
K-Ras, microtubules and other unidentiﬁed molecules and
aﬀects the Ras signaling pathway. This may explain the rapid
elevation of phosphorylated Erk on estrogen stimulation. The
anti-tumor drug, paclitaxel, which is often used in the treat-
ment. of breast cancer, has been shown to associate with
polymerized microtubules and aﬀect Ras-dependent signaling
events [23]. This suggests that paclitaxel might also function
by dissociating the signaling complex that involves ERa, K-
Ras, and microtubules.
Association between the AF-1 domain and microtubules
also tells us that microtubules are not used as tracks when ERa
is transported to the plasma membrane, because the AF-1
domain needs to associate with microtubules at the cytoplasm
before translocation if microtubules are used as tracks. Al-
though membrane translocation is an important step for the
non-genomic action of ERa, the precise mechanism is still
elusive.
Ligand-dependent redistribution of both tubulins and ERa
toward plasma membrane strongly suggests physical associ-
ation between these molecules. To show the interaction of
full-length ERa and tubulins, immunoprecipitation of tub-
ulins or ERa was attempted several times using MCF-7 and
Cos-7 cells. However, no association between tubulins and
endogenous ERa was observed (data not shown). Immu-
nocytostaining revealed that most of the full-length ERa
was expressed in the nucleus and this situation was not
improved even when membrane localizing sequence was at-
tached to full-length ERa. Therefore, we concluded that our
antibodies are not sensitive enough to detect the small
population of membrane-localizing full-length ERa by im-
munoprecipitation.
It remains to be elucidated whether translocation of the
small part of tubulins is a consequence of ERa translocation or
an independent event. Nevertheless, this observation may in-
dicate biological cooperation between ERa and tubulins.
It is also possible that the association of ERa and tubulins
might contribute to the stabilization of microtubules, sincemAF1 has higher aﬃnity with polymerized tubulin and tubulin
was well visualized at the plasma membrane when ERa was
co-localized.
Hsp70 was shown to be another molecule that associates
with the AF-1 domain expressed outside the nucleus. This
association was not restricted at the membrane. The physi-
ological role of the association between the AF-1 domain and
Hsp70 is unclear. One possibility is that this association is
involved in the degradation of cytoplasmic ERa. The gluco-
corticoid receptor, another member of the nuclear receptor
superfamily, is shown to associate with Hsp90. CHIP, a U-
box protein that has ubiquitin ligase activity, was shown to
interact directly with Hsp90 and promote the degradation of
glucocorticoid receptor [24]. CHIP was originally found as a
Hsp70 interacting protein, and is also shown to localize
outside the nucleus and to promote the degradation of Hsp70
bound protein [25]. Therefore, it is conceivable that in the
case of ERa, Hsp70 mediates the degradation of cytoplasmic
population of ERa. The degradation of ERa inside the nu-
cleus was shown to be regulated diﬀerently depending on
whether ERa is liganded or unliganded, and this mode of
degradation generates a cyclic rhythm in the recruitment of
ERa on estrogen-responsive promoters [26]. Hsp70 may be
involved in the diﬀerent regulation of ERa turnover outside
the nucleus, which reﬂects the diﬀerent functions of ERa
outside the nucleus.
We also showed that tyrosine phosphorylation of the AF-2
domain occurs at the plasma membrane. It was previously
reported that the AF-2 domain of ERa is phosphorylated on
estrogen stimulation [15]. However, it was not clear whether
the AF-2 domain is phosphorylated before or after membrane
translocation. Our results favor the latter scenario. As the AF-
2 domain without the membrane-targeted signal was not
phosphorylated, the tyrosine kinases responsible for AF-2
phosphorylation localize strictly in the membranous area.
Therefore, we assume that AF-2 phosphorylation does not
regulate membrane translocation itself and that estrogen
stimulation elicits the membrane translocation of ERa through
interaction independent of phosphotyrosine.
So, what is the role of tyrosine phosphorylation of the AF-
2 domain at the plasma membrane? Does phosphotyrosine
mediate speciﬁc signals when the receptor translocates to the
plasma membrane? Despite several attempts at puriﬁcation,
we have not yet identiﬁed the AF2-associated proteins. One
of the factors that prevented the identiﬁcation of the associ-
ated proteins was that the tyrosine-phosphorylated popula-
tion of the AF-2 domain fragment was extremely small. The
phosphorylation of the membrane-localized AF-2 domain
was hardly detected by transient transfectants (data not
shown). We managed to detect tyrosine phosphorylation of
the membrane-localized AF-2 domain using stable transfec-
tants. As long as the phosphorylated population of the
membrane-localized AF-2 domain is small, only a small
amount of molecules is supposed to bind to the AF-2 domain
in a phosphotyrosine-dependent manner. This may be the
reason that the previously reported association of membrane-
localized AF-2 and c-Src [15] was not detected using our
method (data not shown). Another possible factor that pre-
vented the identiﬁcation of the associated proteins is that AF-
2 domain-bound proteins require the other domains of ERa
to stabilize their association. In this case, longer ERa con-
structs would be needed to purify AF-2-associated proteins.
344 K. Azuma et al. / FEBS Letters 577 (2004) 339–344However, this is technically diﬃcult because strong nuclear
localization signals in the DBD and hinge region prevent the
membrane localization of longer constructs, even though the
membrane-targeting signal was attached to them (data not
shown).
Another limitation of this puriﬁcation method was that only
proteins existing abundantly in the cytoplasm, such as tubulins
and Hsp70, were identiﬁed as AF-1 domain-associated pro-
teins. It is possible that signaling molecules, which are not
expressed abundantly enough to be detected using our method,
interact with the AF-1 or AF-2 domain at the plasma mem-
brane and play an important role. Further improvement in our
puriﬁcation and identiﬁcation method is necessary to charac-
terize these molecules.
In conclusion, we have shown that the AF-1 domain of ERa
interacts with microtubules at the plasma membrane, and
Hsp70 outside the nucleus. We also demonstrated that the AF-
2 domain of ERa is phosphorylated at the plasma membrane.
We hypothesize that ERa forms a complex with microtubule-
associated signaling molecules and phosphotyrosine-depen-
dent AF-2-associated molecules. However, the whole view of
the ERa complex is still unclear. To understand the patho-
logical function of ERa in breast cancers, further investigation
is required. This will lead to further improvement in breast
cancer therapy and also bring about a deeper understanding of
the physiological processes in which nuclear receptors are
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